Showing results (241-250 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|October 9, 2001
Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approachC Le Pen, W Rozenbaum, A Downs, et al.HIV Clinical Trials|October 9, 2001
GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudineK Arasteh, R Wood, M Müller, et al.HIV Clinical Trials|October 9, 2001
Tuberculosis and HIV infection: epidemiology, immunology, and treatmentN W Schluger, J BurzynskiHIV Clinical Trials|October 9, 2001
Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for antiretroviral-naive patientsC G Rodríguez, J Vila, A F Capurro, et al.HIV Clinical Trials|October 9, 2001
Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individualsG Touloumi, V Paparizos, H Sambatakou, et al.HIV Clinical Trials|May 11, 2006
Randomized trials stopped early for harm in HIV/AIDS: a systematic surveyEdward Mills, Curtis Cooper, Ping Wu, et al.HIV Clinical Trials|March 29, 2006
Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD studyJ Santos, R Palacios, M López, et al.HIV Clinical Trials|March 29, 2006
Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathyChristian Herzmann, Margaret A Johnson, Mike YouleHIV Clinical Trials|June 29, 2005
Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patientsJames Hellinger, Calvin Cohen, Anne Morris, et al.HIV Clinical Trials|November 25, 2004
Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studiesSrilatha Edupuganti, David Weber, Charles PoolePageof 68